Tocilizumab in COVID-19: Enthusiasm vs. evidence

Autor:	Paola Zena-Huancas, Mayte Bryce-Alberti, Arianna Portmann-Baracco, Franco Leon-Jimenez
Jazyk:	angličtina
Rok vydání:	2021
Předmět:	Pulmonary and Respiratory Medicine medicine.medical_specialty 2019-20 coronavirus outbreak life threat pneumopericardium drug safety Coronavirus disease 2019 (COVID-19) Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Case Report macromolecular substances mortality rate clinical decision making Article law.invention chemistry.chemical_compound coronavirus disease 2019 tocilizumab Tocilizumab Randomized controlled trial male law Internal medicine middle aged medicine human randomized controlled trial (topic) outcome assessment clinical article C reactive protein treatment business.industry adult evidence based practice single drug dose COVID-19 clinical trial medicine.disease clinical feature drug efficacy female chemistry disease severity Immunoglobulin G1 Cytokine storm business lung embolism high flow nasal cannula therapy
Zdroj:	Lung India : Official Organ of Indian Chest Society
Popis:	Based on the pathophysiological characterization of COVID-19, initial studies suggested the use of tocilizumab (TCZ), a recombinant humanized monoclonal antibody of the immunoglobulin G1 class, for management of the cytokine storm witnessed in severe cases. Thus, we decided to present a case series of 18 patients with severe COVID-19 treated with TCZ at our hospital. Our results coincide with the fact that the routine use of TCZ in severe COVID-19 is not robustly supported. We believe that the efficacy and safety of this drug and other related molecules should be validated in large randomized clinical trials.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b63ecf8e6649992af363694b426c47f3 https://hdl.handle.net/20.500.12866/10191 Zobrazit plný text záznamu